MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and medical imaging, is pleased to announce that it has joined the Amazon Web Services (“AWS”) Partner Network (“APN”) and secured a significant new iRWD™ client, an undisclosed computational biotechnology organization, via the AWS Marketplace.
The APN is a global community of AWS partners that leverages programs, expertise, and resources to build, market, and sell customer offerings.
“As we enter into a stage of anticipated rapid growth, we are excited to have joined the APN global community, a powerful new channel through which OneMedNet is now able to offer potential new customers comprehensive access to valuable, regulatory-grade clinical data across our growing iRWD™ network,” said Aaron Green, OneMedNet’s President and CEO. “AWS has long been recognized as the leading cloud services provider and it is an honor to meet their rigid standards and bring their technical advantages to OneMedNet customers.”
“Choosing to partner with OneMedNet through the APN was a critical decision for us,” commented senior leadership from the new client company. “The convenience and user-friendly nature of the AWS Marketplace made it incredibly easy to discover and engage with OneMedNet. Working with their team, we were able to access precisely curated clinical data, which was crucial for our research and development initiatives. The responsiveness and expertise of the OneMedNet team have significantly enhanced our capabilities, allowing us to leverage regulatory-grade clinical data with ease.”
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology, and cardiology. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Stephen Kilmer, Investor Relations
Phone: 647.872.4849
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Michael Wong, Director of Marketing
Phone: 800.918.7189
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.97 |
Daily Change: | 0.04 4.08 |
Daily Volume: | 462,777 |
Market Cap: | US$27.150M |
December 02, 2024 September 26, 2024 July 26, 2024 June 14, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB